They need 23 mil for Phase 2adjuntive, if they take it all the way through Phase 3 they will need another 55 mil. Currently 80 mil has been raised and this has been an eight year journey, actually longer.
Average Big Pharma spend for a block buster is now about $1.5 billion.
My crytal ball broke years ago, but now that patent is improved I think they will layer the financing and not have much trouble at all.
I previously posted the comparitive to AGN Naurex deal assuming Phase 2 was completely diluted at $1.00 Came up to about $30.00 a share or so not giving any credit to this being oral, which is huge. That was worse case scenario.
I hope they do a strategic partnership or license arrangement with big Pharma, less dilution and they are experts at trials. It is beneficial for any Big Pharma to buy out VTGN after and assuming a successful Phase 2 simply because it gives the acquiring company the flexibity to craft the last leg of the trial and the FDA submission to suit their plan.
Still along way to go, but I assume they will not have issues raising money now, and with a great outcome from NIH raising money should be a breeze and hopefully at much higher PPS.
I think the monthly cash burn is about 500k
News 
Market Data 
Discover 
